Ankylosing spondylitis is a common immunologic disease in rheumatology, and the disease is currently incurable. Early detection of the disease can be controlled in about 90% of patients, and the prognosis is good. Ankylosing spondylitis is an autoimmune disease with inflammation of the sacroiliac joints and spinal attachment points as the main symptom. Progression of the disease can occur in the large joints of the limbs, intervertebral disc fibrous ring, connective tissue fibrosis, ossification, as well as joint ankylosis and fusion. In addition to extra-articular lesions, there may be invasion of multiple systems throughout the body, accompanied by the manifestations of a variety of diseases. Early ankylosing spondylitis lesions are relatively mild or self-limiting, and if patients can make a clear diagnosis, standardize treatment, and functionally rehabilitate at an early stage, they can effectively alleviate the systemic inflammatory response, reduce local pain, stiffness and other symptoms, and slow down the progression of the disease. Most of the early patients can engage in normal work and life after active intervention, and the survival period is no different from the normal population. A small number of patients may show persistent progression of the disease and develop severe disability at an early stage. Therefore, early diagnosis and treatment of the disease can effectively improve the prognosis.